Q1 2024 Earnings Forecast for Selecta Biosciences, Inc. Issued By HC Wainwright (NASDAQ:SELB)

Selecta Biosciences, Inc. (NASDAQ:SELBGet Rating) – HC Wainwright issued their Q1 2024 earnings estimates for shares of Selecta Biosciences in a research report issued to clients and investors on Tuesday, March 7th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.11) per share for the quarter. The consensus estimate for Selecta Biosciences’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Selecta Biosciences’ Q2 2024 earnings at ($0.10) EPS, Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.08) EPS and FY2024 earnings at ($0.39) EPS.

Selecta Biosciences (NASDAQ:SELBGet Rating) last posted its quarterly earnings results on Thursday, March 2nd. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. Selecta Biosciences had a net margin of 31.94% and a return on equity of 15.67%. The company had revenue of $16.80 million for the quarter, compared to the consensus estimate of $12.72 million.

Other research analysts also recently issued reports about the stock. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Selecta Biosciences in a research report on Friday, March 3rd. Mizuho reduced their price target on shares of Selecta Biosciences from $8.00 to $5.00 in a research report on Friday, March 3rd. Finally, Canaccord Genuity Group reduced their price target on shares of Selecta Biosciences from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, January 31st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Selecta Biosciences presently has an average rating of “Moderate Buy” and an average target price of $6.00.

Selecta Biosciences Trading Up 2.0 %

Selecta Biosciences stock opened at $1.55 on Wednesday. The firm’s 50-day moving average is $1.61 and its 200-day moving average is $1.56. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.91 and a current ratio of 5.91. Selecta Biosciences has a 1 year low of $0.65 and a 1 year high of $2.73. The company has a market cap of $237.64 million, a P/E ratio of 11.92 and a beta of 1.17.

Hedge Funds Weigh In On Selecta Biosciences

Several large investors have recently bought and sold shares of SELB. Price T Rowe Associates Inc. MD increased its stake in Selecta Biosciences by 25.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 21,810 shares of the company’s stock valued at $29,000 after buying an additional 4,464 shares during the period. Eqis Capital Management Inc. acquired a new position in Selecta Biosciences during the 1st quarter valued at about $30,000. Beacon Pointe Advisors LLC acquired a new position in Selecta Biosciences during the 1st quarter valued at about $33,000. Prudential Financial Inc. grew its stake in shares of Selecta Biosciences by 161.6% in the 2nd quarter. Prudential Financial Inc. now owns 27,000 shares of the company’s stock worth $35,000 after purchasing an additional 16,680 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Selecta Biosciences in the 3rd quarter worth approximately $38,000. Institutional investors and hedge funds own 40.25% of the company’s stock.

Insider Buying and Selling

In other Selecta Biosciences news, CEO Carsten Brunn sold 27,597 shares of the firm’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $1.13, for a total transaction of $31,184.61. Following the transaction, the chief executive officer now owns 799,486 shares of the company’s stock, valued at approximately $903,419.18. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 30.50% of the company’s stock.

About Selecta Biosciences

(Get Rating)

Selecta Biosciences, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.

Recommended Stories

Earnings History and Estimates for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.